Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • batzem batzem Dec 3, 2007 11:07 PM Flag

    Wachovia Report

    Starts coverage of SUPG with a market perform rating, Paraphrasing says they have spoken to many clinicians who all believe survivial benifit demonstrated by Vidaza is a a class effect and believe EORTC study will show a benifit but question the magnitude. Quoting " However concern resides in the fact that that the study has capped the maximum number of cycles at eight and there is a wide expectation that the median will actually be five cycles .As a result the protocol may have capped the potential survival advantages setting the stage for a less than optimal final result compared to Vidaza."
    Again paraphrasing state pipeline is intriguing but way to early to assign any value. Believe Cilag a very strong EU marketing partner and believe the next major potential for Supg is not till first half 09 when Dacogen is approved in EU.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT